EGFR and non-small cell lung carcinoma: Erlotinib and gefitinib, as oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), are commonly used as second- or third-line drugs [2,3], and are sometimes also used in first-line therapy for advanced or metastatic NSCLC [4,5].